DEE6A is caused by pathogenic variants in the SCN1A gene on chromosome 2. The condition follows autosomal dominant inheritance, per the inheritance data in this packet. ClinGen validity data for the specific SCN1A–DEE6A gene-disease relationship were not certified in this packet; a ClinGen evidence classification was not available for SCN1A at the time this packet was assembled. GeneReviews explains that abnormal SCN1A channels disproportionately affect GABA-ergic inhibitory neurons, producing a net increase in neuronal excitability. The pathophysiological mechanism involves loss of function of the Nav1.1 sodium channel subunit encoded by SCN1A, disrupting the balance between excitatory and inhibitory neurotransmission.

GeneReviews identifies the following as suggestive clinical features that prompt consideration of SCN1A molecular genetic testing: precipitation of seizures by fever, warmth, or vaccination; prolonged or hemiconvulsive seizures; and seizure provocation by overstimulation or flashing patterns. Per GeneReviews, the diagnostic workup encompasses evaluation of the full SCN1A-related spectrum, which includes both mild (GEFS+) and severe (Dravet syndrome) phenotypes. GeneReviews describes differential diagnoses relevant to the SCN1A spectrum, including conditions caused by variants in genes with overlapping epilepsy phenotypes. Molecular genetic testing of SCN1A is a component of the evaluation when the characteristic clinical features are present, as documented in GeneReviews.

No FDA-approved treatments were listed in the approved_treatments field of this packet at the time of data assembly. GeneReviews provides context for the pharmacological management landscape. Per GeneReviews, seizure control is critical in this population given the risk of SUDEP and seizure-related neurological injury. Pharmacological management focuses on the mechanism of abnormal SCN1A channel activity and its disproportionate effect on GABA-ergic neurons. GeneReviews identifies several anti-seizure medications (ASMs) that are documented to worsen SCN1A-related seizures and are therefore not used in clinical practice for this condition: carbamazepine, lamotrigine, and vigabatrin (associated with induction or increase of myoclonic seizures), and phenytoin (associated with seizure worsening and choreoathetosis). This packet contains 19 orphan drug designations; designation status does not indicate FDA approval or confirmed efficacy. No patient-specific dosing, agent selection, or clinical management guidance is derived from this packet.

Certified natural history data were not available in this packet. GeneReviews describes the natural history of SCN1A seizure disorders as strongly influenced by seizure phenotype: the severe end of the spectrum (Dravet syndrome) is associated with frequent treatment-resistant seizures, intellectual disability, and elevated SUDEP risk. GeneReviews notes the variable expressivity of SCN1A pathogenic variants and the resulting heterogeneity in long-term outcomes, with phenotype varying even within families carrying the same variant. Prognosis data certified specifically to the DEE6A MONDO entity were not available in this packet beyond these characterizations from GeneReviews.

The research landscape digest for DEE6A encompasses 430 classified publications, including 130 reviews and 45 case reports, with representation across gene therapy, biomarker, and recent trial-linked research areas, per internal Kisho classification. Active recruiting trials indexed to this condition include NCT06872125 (a double-blind study evaluating efficacy, safety, and tolerability of Zorevunersen, Phase 2/3, RECRUITING per ClinicalTrials.gov) and NCT05419492 (evaluating the safety and efficacy of ETX101 in infants and children, RECRUITING per ClinicalTrials.gov). GeneReviews identifies investigational approaches including thalamic deep brain stimulation (DBS), which has been reported in two pediatric cases with ten-year follow-up. GeneReviews also notes lacosamide and verapamil as subjects of preliminary investigation, though neither has been formally studied in SCN1A seizure disorders as of the GeneReviews chapter date. The research pipeline includes gene therapy strategies, consistent with the has_gene_therapy_pubs signal in the research landscape digest.